{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:03:34Z","timestamp":1783091014544,"version":"3.54.6"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.nbd.2020.105173","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T02:12:59Z","timestamp":1604715179000},"page":"105173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity"],"prefix":"10.1016","volume":"147","author":[{"given":"Olga","family":"Varea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f2nica","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Prats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan J.","family":"Guinovart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2020.105173_bb0005","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/glia.23463","article-title":"Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease","volume":"66","author":"Auge","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.nbd.2020.105173_bb0010","doi-asserted-by":"crossref","first-page":"017","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2020.105173_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-030-27480-1_2","article-title":"Brain glycogen structure and its associated proteins: past, present and future","volume":"23","author":"Brewer","year":"2019","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.nbd.2020.105173_bb0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0165-0173(99)00003-X","article-title":"Corpora-amylacea and the family of polyglucosan diseases","volume":"29","author":"Cavanagh","year":"1999","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.nbd.2020.105173_bb0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0300985818758471","article-title":"Accumulation of Laforin and other related proteins in canine Lafora disease with EPM2B repeat expansion","volume":"55","author":"Chambers","year":"2018","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.nbd.2020.105173_bb0030","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0003-2697(76)90014-2","article-title":"A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes","volume":"71","author":"Chan","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.nbd.2020.105173_bb0035","first-page":"47","article-title":"Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B","volume":"95","author":"Chan","year":"2005","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.nbd.2020.105173_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2017.00261","article-title":"Regulation of microglia and macrophage polarization via apoptosis signal-regulating kinase 1 silencing after ischemic\/hypoxic injury","volume":"10","author":"Cheon","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2020.105173_bb0045","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/hmg\/ddr590","article-title":"Lafora bodies and neurological defects in Malin-deficient mice correlate with impaired autophagy","volume":"21","author":"Criado","year":"2012","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.nbd.2020.105173_bb0050","first-page":"2010","article-title":"Beta Regression in R","volume":"1","author":"Cribari-Neto","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.nbd.2020.105173_bb0055","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s11910-007-0066-7","article-title":"Advances in lafora progressive myoclonus epilepsy","volume":"7","author":"Delgado-Escueta","year":"2007","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.nbd.2020.105173_bb0060","doi-asserted-by":"crossref","first-page":"25372","DOI":"10.1074\/jbc.M110.148668","article-title":"Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin","volume":"285","author":"DePaoli-Roach","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.105173_bb0065","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/jcbfm.2012.200","article-title":"Impairment in long-term memory formation and learning-dependent synaptic plasticity in mice lacking glycogen synthase in the brain","volume":"33","author":"Duran","year":"2013","journal-title":"J. Cerebral Blood Flow Metab. Off. J. Int. Soc. Cerebral Blood Flow Metab."},{"key":"10.1016\/j.nbd.2020.105173_bb0070","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2020.105173_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10038-005-0321-1","article-title":"Recent advances in the molecular basis of Lafora\u2019s progressive myoclonus epilepsy","volume":"51","author":"Ganesh","year":"2006","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.nbd.2020.105173_bb0080","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1073\/pnas.0503285102","article-title":"Insights into Lafora disease: Malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin","volume":"102","author":"Gentry","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2020.105173_bb0085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/bimj.200810425","article-title":"Simultaneous inference in general parametric models","volume":"50","author":"Hothorn","year":"2008","journal-title":"Biom. J."},{"issue":"13","key":"10.1016\/j.nbd.2020.105173_bb0090","first-page":"2017","article-title":"lmerTest package: tests in linear mixed effects models","volume":"1","author":"Kuznetsova","year":"2017","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.nbd.2020.105173_bb0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s12035-019-01842-z","article-title":"Reactive glia-derived Neuroinflammation: a novel Hallmark in Lafora progressive myoclonus epilepsy that progresses with age","volume":"57","author":"Lahuerta","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2020.105173_bb0100","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s12035-016-9884-4","article-title":"Inflammation in Lafora disease: evolution with disease progression in Laforin and Malin Knock-out mouse models","volume":"54","author":"L\u00f3pez-Gonz\u00e1lez","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2020.105173_bb0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.expneurol.2012.04.008","article-title":"Ontogeny of Lafora bodies and neurocytoskeleton changes in Laforin-deficient mice","volume":"236","author":"Machado-Salas","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2020.105173_bb0110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","article-title":"Lafora disease - from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2020.105173_bb0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.23899","article-title":"Inhibiting glycogen synthesis prevents Lafora disease in a mouse model","volume":"74","author":"Pederson","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2020.105173_bb0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/hmg\/ddr452","article-title":"Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease","volume":"21","author":"Puri","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2020.105173_bb0125","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/hmg\/ddy044","article-title":"Astrocytes: new players in progressive myoclonus epilepsy of Lafora type","volume":"27","author":"Rubio-Villena","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2020.105173_bb0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.stem.2007.03.002","article-title":"Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss","volume":"1","author":"Ruzankina","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.nbd.2020.105173_bb0135","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.biocel.2015.10.030","article-title":"Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the Malin-laforin E3-ubiquitin ligase complex","volume":"69","author":"S\u00e1nchez-Mart\u00edn","year":"2015","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.nbd.2020.105173_bb0140","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1007\/s00018-015-1995-y","article-title":"Macrophage polarization in pathology","volume":"72","author":"Sica","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.nbd.2020.105173_bb0145","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1042\/BCJ20170469","article-title":"A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease","volume":"474","author":"Solmesky","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2020.105173_bb0150","doi-asserted-by":"crossref","first-page":"33816","DOI":"10.1074\/jbc.M807428200","article-title":"Abnormal metabolism of glycogen phosphate as a cause for Lafora disease","volume":"283","author":"Tagliabracci","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.105173_bb0155","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1021\/acs.jmedchem.9b01851","article-title":"Discovery and development of small-molecule inhibitors of glycogen synthase","volume":"63","author":"Tang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.nbd.2020.105173_bb0160","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.113.301453","article-title":"Transcriptional control of macrophage polarization","volume":"33","author":"Tugal","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.nbd.2020.105173_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002037","article-title":"PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease","volume":"7","author":"Turnbull","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.nbd.2020.105173_bb0170","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1212\/WNL.0b013e318219faf6","article-title":"Lafora bodies in skeletal muscle are fiber type specific","volume":"76","author":"Turnbull","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2020.105173_bb0175","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/emmm.201100174","article-title":"Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease","volume":"3","author":"Valles-Ortega","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.nbd.2020.105173_bb0180","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-0038-1675238","article-title":"Lafora disease: a review of molecular mechanisms and pathology","volume":"49","author":"Verhalen","year":"2018","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.nbd.2020.105173_bb0185","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nn1998","article-title":"Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy","volume":"10","author":"Vilchez","year":"2007","journal-title":"Nat. Neurosci."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996120304484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996120304484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:24:31Z","timestamp":1760851471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996120304484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":37,"alternative-id":["S0969996120304484"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2020.105173","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2020.105173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105173"}}